Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Thematic (Sector/Industry)

<ul><li>Rescheduling Is the Single Biggest Catalyst for US Cannabis.</li><li>It removes the 280E tax burden that prevents US plant-touching operators from deducting ordinary operating expenses, which in many cases doubles the effective tax rate.</li><li>280E only applies to Schedule I and II drugs, so the proposed move to Schedule III would remove 280E.</li></ul>

Rescheduling Is the Single Biggest Catalyst for US Cannabis.It removes the 280E tax burden that prevents US plant-touching operators from deducting ordinary operating expenses, which in many cases doubles the effective tax rate.280E only applies to Schedule I and II drugs, so the proposed move to Schedule III would remove 280E.

WTR Small-Cap Spotlight Recap - Five Cannabis Trends for 2025

<ul><li>For psychedelics, 2024 could be defined by the disappointing outcome of the FDA’s August review decision on Lykos Therapeutics’ (formerly MAPS) NDA for its MDMA-AT candidate for PTSD.</li><li>The FDA’s decision flew in the face of the anticipatory excitement following the NDA submission and award of breakthrough therapy designation earlier in the year following impressive results from Lykos’ two- part Phase 3 trial.</li><li>However, as disappointing as it is, particularly for the many millions of PTSD sufferers and Lykos, which subsequently reduced its workforce by 75%, in the grand scheme of things, this is only a temporary setback.</li></ul>

For psychedelics, 2024 could be defined by the disappointing outcome of the FDA’s August review decision on Lykos Therapeutics’ (formerly MAPS) NDA for its MDMA-AT candidate for PTSD.The FDA’s decision flew in the face of the anticipatory excitement following the NDA submission and award of breakthrough therapy designation earlier in the year following impressive results from Lykos’ two- part Phase 3 trial.However, as disappointing as it is, particularly for the many millions of PTSD sufferers and Lykos, which subsequently reduced its workforce by 75%, in the grand scheme of things, this is only a temporary setback.

Shroom Shmooz Psychedelics: Trends to Watch Going into 2025

<ul><li>US cannabis stocks climbed higher last week, with the US cannabis MSOS ETF gaining 5.15%, while the global YOLO ETF lost 2.04%.</li><li>Among the larger MSOs, Verano (NEO: VRNO, OTCQX: VRNOF) had the best week, jumping 9.84%.</li><li>Verano rose after sharing it authorized a $50 million share repurchase program on Monday. </li></ul>

US cannabis stocks climbed higher last week, with the US cannabis MSOS ETF gaining 5.15%, while the global YOLO ETF lost 2.04%.Among the larger MSOs, Verano (NEO: VRNO, OTCQX: VRNOF) had the best week, jumping 9.84%.Verano rose after sharing it authorized a $50 million share repurchase program on Monday. 

The Highlights - Cannabis News for the Week Ending June 21, 2024

<ul><li>Despite relatively strong earnings, the US cannabis MSOS ETF fell 3.52%, while the global YOLO ETF dropped 2.21%.</li><li>With four of the five Tier 1 MSOs reporting, on average they have beaten revenue consensus by 2.27% and adjusted EBITDA consensus by 9.15%. See page two for more details on Tier 1 earnings results.</li><li>Verano (NEO: VRNO, OTCQX: VRNOF) reported better-than-expected results last week and Co- Founder, Chairman, and CEO George Archos joined us on Higher Exchanges. </li></ul>

Despite relatively strong earnings, the US cannabis MSOS ETF fell 3.52%, while the global YOLO ETF dropped 2.21%.With four of the five Tier 1 MSOs reporting, on average they have beaten revenue consensus by 2.27% and adjusted EBITDA consensus by 9.15%. See page two for more details on Tier 1 earnings results.Verano (NEO: VRNO, OTCQX: VRNOF) reported better-than-expected results last week and Co- Founder, Chairman, and CEO George Archos joined us on Higher Exchanges. 

The Highlights - Cannabis News for the Week Ending May 10, 2024

<ul><li>Poseidon co-founders Emily and Morgan Paxhia joined us on the Water Tower Hour podcast to discuss the rescheduling news.</li><li>Those interested can listen to this podcast on Apple Podcasts, Spotify, or on our website.</li><li>On April 30, 2024, the DEA reportedly agreed with the HHS recommendation to reclassify cannabis from Schedule I to Schedule III. </li></ul>

Poseidon co-founders Emily and Morgan Paxhia joined us on the Water Tower Hour podcast to discuss the rescheduling news.Those interested can listen to this podcast on Apple Podcasts, Spotify, or on our website.On April 30, 2024, the DEA reportedly agreed with the HHS recommendation to reclassify cannabis from Schedule I to Schedule III. 

Water Tower Hour Recap - Cannabis Rescheduling Review with Poseidon

United States

The AdvisorShares Pure US Cannabis ETF is an actively managed exchange-traded fund incorporated in the USA.  The fund seeks to seeks long-term capital appreciation by investing in the US Cannabis industry.

AdvisorShares Pure US Cannabis ETF (MSOS US)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

AdvisorShares Pure US Cannabis ETF (MSOS US)

WTR Small-Cap Spotlight Recap - Five Cannabis Trends for 2025

Rescheduling Is the Single Biggest Catalyst for US Cannabis. It removes the 280E tax burden that prevents US plant-touching operators from...

Water Tower Research

Shroom Shmooz Psychedelics: Trends to Watch Going into 2025

For psychedelics, 2024 could be defined by the disappointing outcome of the FDA’s August review decision on Lykos Therapeutics’ (formerly MAPS) NDA...

Water Tower Research

The Highlights - Cannabis News for the Week Ending June 21, 2024

US cannabis stocks climbed higher last week, with the US cannabis MSOS ETF gaining 5.15%, while the global YOLO ETF lost 2.04%.

Water Tower Research

The Highlights - Cannabis News for the Week Ending May 10, 2024

Verano (NEO: VRNO, OTCQX: VRNOF) reported better-than-expected results last week and Co- Founder, Chairman, and CEO George Archos joined us on...

Water Tower Research

Water Tower Hour Recap - Cannabis Rescheduling Review with Poseidon

Poseidon co-founders Emily and Morgan Paxhia joined us on the Water Tower Hour podcast to discuss the rescheduling news.

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)